Atriva Therapeutics

Atriva aims to develop new antiviral therapies against different respiratory viral infections. Founded in 2015, Atriva attracted seasoned experts in virology and drug development to form a unique venture targeting the fast and successful validation of a novel approach to fight infectious diseases.

MEK Inhibitors

Inhibitors of certain cellular signaling pathways, the so called “MEK-Inhibitors”, have shown a superior antiviral activity by blocking viral replication. This creates an unprecedented potential for truly efficacious and safe therapeutics against numerous viral infections. A key benefit of this approach is that there is no risk of resistance formation in the virus.

More information

https://www.atriva-therapeutics.com/